文献速递浆细胞疾病

循环肿瘤浆细胞超过2%定义浆细胞白血病样多发性骨髓瘤

More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.
PubMed 文献 · J Clin Oncol · 2022-10-31

研究通过多参数流式细胞术检测395例不适合移植的新诊断多发性骨髓瘤患者循环肿瘤浆细胞(CTCs),确定2%为识别超高危浆细胞白血病样骨髓瘤的界值,并在185例适合移植患者及GEM-CLARIDEX试验280例独立队列中验证;2%-20% CTCs患者无进展生存和总生存显著短于<2%者,且结局与原发性浆细胞白血病相当。

要点

  • ≥2%循环肿瘤浆细胞是多发性骨髓瘤中隐藏的原发性浆细胞白血病的生物标志物。
  • 2%-20% CTCs患者无进展生存3.1个月 vs <2%者15.6个月(P<.001)。
  • 2%-20% CTCs患者总生存14.6个月 vs <2%者33.6个月(P=.023)。

核心结论

  • ≥2%循环肿瘤浆细胞是隐藏的原发性浆细胞白血病的生物标志物,支持在多发性骨髓瘤诊断检查中通过流式细胞术评估循环肿瘤浆细胞。

研究设计与样本

  • 研究用多参数流式细胞术评估395例新诊断不适合移植的多发性骨髓瘤患者的循环肿瘤浆细胞水平以确定界值。
  • 界值在185例适合移植的多发性骨髓瘤患者中测试,并在GEM-CLARIDEX试验中280例不适合移植患者的独立队列中验证。
  • 使用已发表的最大真实世界原发性浆细胞白血病患者队列进行生存比较,并对当前5%的原发性浆细胞白血病诊断阈值提出挑战。

主要发现

  • 新诊断不适合移植的多发性骨髓瘤患者中,2%-20% CTCs组无进展生存3.1个月 vs <2%组15.6个月(P<.001)。
  • 新诊断不适合移植的多发性骨髓瘤患者中,2%-20% CTCs组总生存14.6个月 vs <2%组33.6个月(P=.023)。
  • 2%界值在适合移植的多发性骨髓瘤患者中亦适用,并在GEM-CLARIDEX试验独立队列中成功验证。
  • 2%-20% CTCs患者与原发性浆细胞白血病患者结局相当,均较差。
  • 流式细胞术与形态学评估CTCs的平均差异低,2%-5% CTCs患者与5%-20% CTCs患者结局相似。

关键数值与推荐

  • 2%-20% CTCs组无进展生存3.1个月 vs <2%组15.6个月(P<.001)。
  • 2%-20% CTCs组总生存14.6个月 vs <2%组33.6个月(P=.023)。

临床怎么用

  • 作者支持在多发性骨髓瘤诊断检查中通过流式细胞术评估循环肿瘤浆细胞。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by ≥ 20% circulating plasma cells (CTCs) until 2021, when this threshold was decreased to ≥ 5%. We hypothesized that primary PCL is not a separate clinical entity, but rather that it represents ultra-high-risk multiple myeloma (MM) characterized by elevated CTC levels. METHODS: We assessed the levels of CTCs by multiparameter flow cytometry in 395 patients with newly diagnosed transplant-ineligible MM to establish a cutoff for CTCs that identifies the patients with ultra-high-risk PCL-like MM. We tested the cutoff on 185 transplant-eligible patients with MM and further validated on an independent cohort of 280 transplant-ineligible patients treated in the GEM-CLARIDEX trial. The largest published real-world cohort of patients with primary PCL was used for comparison of survival. Finally, we challenged the current 5% threshold for primary PCL diagnosis. RESULTS: Newly diagnosed transplant-ineligible patients with MM with 2%-20% CTCs had significantly shorter progression-free survival (3.1 v 15.6 months; P < .001) and overall survival (14.6 v 33.6 months; P = .023) than patients with < 2%. The 2% cutoff proved to be applicable also in transplant-eligible patients with MM and was successfully validated on an independent cohort of patients from the GEM-CLARIDEX trial. Most importantly, patients with 2%-20% CTCs had comparable dismal outcomes with primary PCL. Moreover, after revealing a low mean difference between flow cytometric and morphologic evaluation of CTCs, we showed that patients with 2%-5% CTCs have similar outcomes as those with 5%-20% CTCs. CONCLUSION: Our study uncovers that ≥ 2% CTCs is a biomarker of hidden primary PCL and supports the assessment of CTCs by flow cytometry during the diagnostic workup of MM.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Jelinek T, Bezdekova R, Zihala D, et al. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma. J Clin Oncol. 2022. PMID: 36315921. doi:10.1200/JCO.22.01226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。